Pharmather Holdings Ltd PHRRF

PharmaTher Announces Positive Topline Results

[Betteryear2]

100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale

Ketamine was well tolerated with no serious adverse events reported

Study results are adequate to give an effect size in powering a Phase 3 clinical study

PharmaTher planning a Phase 3 clinical study to allow for FDA approval of KETARX™ (ketamine) for Parkinson’s disease under the 505(b)(2) regulatory pathway

TORONTO, March 23, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce positive topline results from the dose-finding and tolerability clinical study (the “Study”) of ketamine for the treatment of levodopa-induced dyskinesia (“LID”) in patients with Parkinson’s disease. The Study results are adequate to give an effect size in powering a Phase 3 clinical study, which is expected to bridge the design with increased treatment duration relative to the Company’s Phase 2 clinical study (NCT04912115).

PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease

[GustheGreek]

Lol, good news (sort of), and it lost more than a third of its value. SHORTS, SHORTS, AND MORE SHORTS! Imo, it's time to jump back in this one.

[hurko87]

This post has been removed in accordance with Community Policy